Novel Targeted Therapeutic Strategies for Ewing Sarcoma. 2022

Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
Group of Experimental Biotherapy and Diagnostic, Department of Advanced Materials, Institute for Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Ewing sarcoma (ES) is an uncommon cancer that arises in mesenchymal tissues and represents the second most widespread malignant bone neoplasm after osteosarcoma in children. Amplifications in genomic, proteomic, and metabolism are characteristics of sarcoma, and targeting altered cancer cell molecular processes has been proposed as the latest promising strategy to fight cancer. Recent technological advancements have elucidated some of the underlying oncogenic characteristics of Ewing sarcoma. Offering new insights into the physiological basis for this phenomenon, our current review examines the dynamics of ES signaling as it related to both ES and the microenvironment by integrating genomic and proteomic analyses. An extensive survey of the literature was performed to compile the findings. We have also highlighted recent and ongoing studies integrating metabolomics and genomics aimed at better understanding the complex interactions as to how ES adapts to changing biochemical changes within the tumor microenvironment.

UI MeSH Term Description Entries

Related Publications

Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
November 2022, Cancers,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
January 2014, Immunotherapy,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
January 2012, ISRN oncology,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
August 2023, Cancers,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
January 2016, F1000Research,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
January 2021, Frontiers in genetics,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
May 2016, Oncogene,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
May 2015, Cancer treatment reviews,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
February 2012, Pediatric hematology and oncology,
Daria Fayzullina, and Sergey Tsibulnikov, and Mikhail Stempen, and Brett A Schroeder, and Naveen Kumar, and Rajesh Kumar Kharwar, and Arbind Acharya, and Peter Timashev, and Ilya Ulasov
January 2020, Case reports in oncological medicine,
Copied contents to your clipboard!